Progesterone in MHT for Protection Against Endometrial Cancer

Key Takeaways

• E3N study links 5+ years progesterone MHT to 2.7‑fold endometrial cancer rise
• Randomized trials show <1% hyperplasia risk with short‑term progesterone
• Long‑term safety beyond three years remains unstudied for oral progesterone
• Sequential 12‑day regimens may allow endometrial rebound, increasing risk
• High estrogen doses may need higher progesterone or progestin for protection

Pulse Analysis

The debate over progesterone’s role in menopausal hormone therapy (MHT) intensified after the Women’s Health Initiative linked combined estrogen‑progestin regimens to higher breast‑cancer rates. In response, clinicians turned to oral micronized progesterone, assuming a safer profile. However, the large French E3N observational cohort, tracking over 80,000 postmenopausal women for an average of eight years, reported a neutral breast‑cancer risk but a striking 2.7‑fold rise in endometrial cancer for users on progesterone‑based MHT beyond five years. This translates a baseline lifetime risk of roughly 3% to 6‑8%, a shift that matters at a population level.

Randomized clinical trials provide a contrasting view for short‑term use. The 1995 PEPI trial and the FDA‑registered Prometrium study demonstrated that adding progesterone to estrogen dramatically reduced endometrial hyperplasia, with rates under 1% in the progesterone arms compared with 64% for estrogen alone. More recent data from the Bijuva combination product, involving 1,835 women over a year, confirmed similarly low hyperplasia incidences (≈0.35%). Yet these studies rarely exceed three years, leaving a data gap for the longer durations common in real‑world practice. Moreover, many of the older trials used sequential dosing (12‑14 days per month), which may permit endometrial rebound and could explain the higher cancer signal seen in the E3N cohort.

Clinicians now face a nuanced decision matrix. For patients on higher estrogen doses (e.g., 75‑100 µg patches), the protective effect of standard‑dose progesterone may be insufficient, prompting consideration of higher progesterone amounts or a switch to a progestin with more consistent bioavailability. Ongoing research, such as the PROBES trial comparing oral estradiol with either 100 mg progesterone or 0.5 mg norethindrone, aims to clarify both breast and endometrial safety over longer periods. Until those results emerge, best practice includes regular endometrial surveillance, adherence counseling, and individualized risk assessment that weighs breast‑cancer concerns against the potential for endometrial malignancy.